Abstract
Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Keywords: Cardiovascular biomarkers, gender differences.
Current Vascular Pharmacology
Title:Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Volume: 11 Issue: 5
Author(s): Erjon Agushi, Borejda Xhyheri and Raffaele Bugiardini
Affiliation:
Keywords: Cardiovascular biomarkers, gender differences.
Abstract: Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Export Options
About this article
Cite this article as:
Agushi Erjon, Xhyheri Borejda and Bugiardini Raffaele, Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050017
DOI https://dx.doi.org/10.2174/1570161111311050017 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Supertargeted Chemistry: Identifying Relationships Between Molecular Structures and their Sub-Cellular Distribution
Current Topics in Medicinal Chemistry Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets